- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00328094
Glycemic Control to Prevent Cardiac Morbidity in Vascular Surgery
Impact of Tight Control of Perioperative Blood Glucose in Patients Undergoing Vascular Surgery on Their Perioperative Cardiovascular and Overall Morbidity and Mortality
Aggressive intraoperative and postoperative management of blood glucose may substantially decrease perioperative cardiovascular and infectious complications in diabetic and non-diabetic patients undergoing vascular surgery.
The purpose of this study is to compare the tight versus traditional blood glucose control in diabetics and non-diabetics undergoing vascular surgery in regard to their postoperative fatal and nonfatal cardiac outcomes, and the secondary effects such as rate of infections, overall morbidity and 30-day mortality.
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a randomized, prospective controlled trial in both diabetic and non diabetic patients undergoing vascular surgery such as abdominal aortic, infra inguinal vascular bypass procedures and amputations, comparing tight versus standard blood glucose control regimens in the operating room, post anesthesia care unit and in the postoperative vascular intensive care unit up to 48 hours and its impact on the cardiovascular, infectious and other morbidity and mortality during the hospital admission and up to 30 days from surgery.
After obtaining informed consent, the study subjects will be randomized to tight versus standard blood glucose control regimens. These regimens will be started in the operating room and continued for the first 48 hours or until their discharge, whichever is earlier. All the patients will be inpatients. Day surgery patients will be excluded.
The anesthesiologist providing patient care will be given either the tight glucose control protocol or the standard sliding scale insulin protocol. In the tight control regimen, target blood glucose is 100-150 mg/dl. If 3 consecutive blood glucose (BG) level >150 mg/dL or 1 BG level >200 mg/dL, then the insulin infusion will be initiated in the tight control group. The insulin infusion rate adjustments will be made based on the blood sugar results. In post anesthetic care unit (PACU) and vascular intensive care unit (VICU), these protocols will be nurse driven. The adjustments will be made based on the current blood sugar levels as well as the insulin infusion rates. They are adjusted in such a way to account for the rate of change of blood sugars and the presence of steroid therapy in the patients. The frequency of blood glucose testing in this group will be every 1-hour until stable (when frequent changes in insulin dosage are no longer necessary, and glucose is in the range of 100 to 150 for 3 consecutive blood sugar checks); then test every 2 hours for 3 consecutive target values and then every 4 hours thereafter. If there is a change in the infusion rates, then blood sugar checks will be done every hour and the cycle followed thereafter.
In the standard sliding scale insulin group, blood sugars will be treated with insulin boluses if the blood sugars go more than 150 mg/dL and blood glucose will be monitored every 4 hours.
These regimens will be initiated after 2 weeks of in-service training for anesthesiologists, post anesthetic care unit (PACU) and vascular intensive care unit (VICU) nurses. The study investigators will provide this training. Insulin infusion in the tight control regimen will be started through pump piggyback to maintenance intravenous infusion as follows. Insulin infusion bags will be made by the pharmacy (100 units in a 100 ml bag). The anesthesiologists in the operating room and PACU, and VICU nurses will perform blood glucose monitoring, bolus insulin administration, and infusion initiation and rate adjustments as specified by the protocol. Blood glucose levels will be tested by finger stick method or arterial line drop sample.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Beth Israel Deaconess Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Abdominal aortic surgery
- Supra and infrainguinal peripheral vascular bypass surgery
- Below knee amputations
- Above knee amputations
- Diabetics and nondiabetics
- American Society of Anesthesiologists (ASA) I-III
Exclusion Criteria:
- Brittle diabetics
- ASA 1V,V
- Second surgery in same admission
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CII, Continuous Insulin Infusion
Continuous intravenous insulin infusion to control glucose to <150 mg/dL in patients undergoing open peripheral vascular bypass surgery
|
Tight glucose control versus standard of care
Other Names:
|
Active Comparator: IIB, Intermittent insulin boluses
Intermittent intravenous insulin insulin boluses to a blood glucose target of <150mg/dL in patients undergoing peripheral vascular bypass surgery
|
Tight glucose control versus standard of care
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Composite (Myocardial Infarction and CHF)
Time Frame: hospital length of stay
|
hospital length of stay
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of Wound Infections
Time Frame: postoperative
|
postoperative
|
Collaborators and Investigators
Investigators
- Principal Investigator: Balachundhar Subramaniam, Beth Israel Deaconess Medical Center, Boston MA
Publications and helpful links
General Publications
- van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001 Nov 8;345(19):1359-67. doi: 10.1056/NEJMoa011300.
- Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg. 1999 Feb;67(2):352-60; discussion 360-2. doi: 10.1016/s0003-4975(99)00014-4.
- Zimmerman CR, Mlynarek ME, Jordan JA, Rajda CA, Horst HM. An insulin infusion protocol in critically ill cardiothoracic surgery patients. Ann Pharmacother. 2004 Jul-Aug;38(7-8):1123-9. doi: 10.1345/aph.1E018. Epub 2004 May 18.
- Kersten JR, Warltier DC, Pagel PS. Aggressive control of intraoperative blood glucose concentration: a shifting paradigm? Anesthesiology. 2005 Oct;103(4):677-8. doi: 10.1097/00000542-200510000-00002. No abstract available.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Atherosclerosis
- Aortic Diseases
- Vascular Diseases
- Peripheral Arterial Disease
- Peripheral Vascular Diseases
- Aneurysm
- Aortic Aneurysm
- Aortic Aneurysm, Abdominal
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Insulin
- Insulin, Globin Zinc
Other Study ID Numbers
- 2005P-000299
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Vascular Disease
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
C. R. BardCromsourceCompletedVascular Diseases, PeripheralGermany, Poland
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
SensomeRecruitingPeripheral Vascular DiseaseBelgium
-
Biotronik, Inc.CompletedPeripheral Vascular Disease | Peripheral Artery DiseaseCanada, United States
-
Biotronik AGBiotronik, Inc.UnknownPeripheral Vascular Disease | Peripheral Artery DiseaseGermany, Belgium, Austria, Switzerland
-
Acotec Scientific Co., LtdRecruitingPeripheral Arterial Disease (PAD) | Peripheral Vascular Disease (PVD)China
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI)Not yet recruitingPeripheral Vascular Disease | Peripheral Artery DiseaseUnited States
-
University of MichiganTerminatedPeripheral Vascular Disease | Peripheral Artery DiseaseUnited States
-
Baylor UniversityNational Institute on Aging (NIA)RecruitingArterial Occlusive Diseases | Peripheral Arterial Disease | Atherosclerosis | Vascular Diseases, PeripheralUnited States
Clinical Trials on continuous intravenous insulin infusion
-
University of New MexicoSanofiCompleted
-
University at BuffaloAmerican Diabetes AssociationCompleted
-
Audai A. HayajnehCompleted
-
Newcastle UniversitySanofi; Medtronic; Newcastle-upon-Tyne Hospitals NHS Trust; Newcastle Primary Care...Completed
-
University Hospital, MontpellierNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaboratorsRecruitingType 1 Diabetes Mellitus With HypoglycemiaFrance
-
King's College LondonUniversity Hospital, Caen; University of LeicesterCompletedDiabetes Mellitus, Type 2
-
First Affiliated Hospital of Guangxi Medical UniversityRecruiting
-
Peking University Third HospitalNot yet recruitingType 2 Diabetes | Pregnancy in DiabeticChina
-
Castilla-La Mancha Health ServiceUniversidad de Córdoba; University of Castilla-La ManchaCompletedType 1 Diabetes MellitusSpain
-
Federico II UniversityTerminatedDiabetes Mellitus | Covid19Italy